Proteomic Aging Clocks Track Biological Age Reversal in Rentosertib Trial
This story is from 2026-09-07. It is preserved in the archive; the latest stories are on the live feed.
Researchers from Insilico Medicine and an international group of academic collaborators have applied six independently developed proteomic aging clocks to blood samples from a Phase IIa trial of the AI-designed drug rentosertib, finding that all six models consistently predicted lower biological ag…
Read the full story at Unite.AI ↗
Timeline · 1 report
- 2026-09-07 09:58 · Unite.AI
Proteomic Aging Clocks Track Biological Age Reversal in Rentosertib Trial